# US 2024/0199627 A1 · Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199627 A1
- Document ID: US20240199627A1
- Status: Published application
- Kind: A1
- Application number: 18/594,898
- Filed: 2024-03-04
- Published: 2024-06-20
- Earliest claimed: 2018-05-25
- Assignees: Cardurion Pharmaceuticals, LLC
- Applicants: Cardurion Pharmaceuticals, Inc.
- Inventors: Suzanne BUTTAR; Mateusz PITAK; Adam Ross PATTERSON; Samuel Alexander STRATFORD; Ioana SOVAGO; Jun XU; Peng ZHOU; Haojuan WEI; Kuangchu DAI
- Web page: https://patentgrep.com/patent/US20240199627A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure relates to crystalline polymorph forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one.

## Claims

### Claim 1

A monohydrate crystalline form of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one

### Claim 2 (depends on 1)

The monohydrate crystalline form in claim 1, wherein the monohydrate crystalline form is Monohydrate Form 1 (MH1), having an XRPD pattern comprising peaks of 2θ angles at about 9.1, 11.5, 16.2, 16.7, 18.2, 18.9, 19.8, 22.6, and 26.4 degrees 2θ, each ±0.2 degrees 2θ.

### Claim 3 (depends on 1)

The monohydrate crystalline form in claim 1, wherein the monohydrate crystalline form is MH1, having an XRPD pattern substantially as shown in FIG. 2A.

### Claim 4 (depends on 1)

The monohydrate crystalline form in claim 1, wherein the monohydrate crystalline form is MH1, having a dehydration endothermic peak at about 40-100° C. and a melting endothermic peak at about 184.4° C. in a differential scanning calorimetry (DSC) thermogram.

### Claim 5 (depends on 1)

The monohydrate crystalline form in claim 1, wherein the monohydrate crystalline form is MH1, having a DSC thermogram substantially in accordance with FIG. 5.

### Claim 6 (depends on 1)

The monohydrate crystalline form in claim 1, wherein the monohydrate crystalline form is MH1, exhibiting dehydration between ambient and about 90° C. with a weight loss of about 3.8% in a thermogravimetric analysis (TGA).

### Claim 7 (depends on 1)

The monohydrate crystalline form in claim 1, wherein the monohydrate crystalline form is MH1, having a TGA substantially in accordance with FIG. 5.

### Claim 8 (depends on 1)

The monohydrate crystalline form in claim 1, wherein the monohydrate crystalline form is MH1, having characteristic absorptions at about 782 cm−1, 1123 cm−1, 1562 cm−1 and 1655 cm−1 in an infrared (IR) spectrum.

### Claim 9 (depends on 1)

The monohydrate crystalline form in claim 1, wherein the monohydrate crystalline form is MH1, having an infrared spectrum substantially in accordance with FIG. 3.

### Claim 10 (depends on 1)

The monohydrate crystalline form in claim 1, wherein the monohydrate crystalline form is Monohydrate Form 2 (MH2), having an XRPD pattern comprising peaks of 2θ angles at about 9.0, 11.6, 15.0, 16.0, 18.6, 19.1, 20.4, or 20.6 degrees 2θ, each ±0.2 degrees 2θ.

### Claim 11 (depends on 1)

The monohydrate crystalline form in claim 1, wherein the monohydrate crystalline form is MH2, having an XRPD pattern substantially as shown in FIG. 7A and FIG. 7B.

### Claim 12 (depends on 1)

The monohydrate crystalline form in claim 1, wherein the monohydrate crystalline form is MH2, having an endothermic peak at about 59.1° C. (±5° C.) and at about 184.7° C. (±5° C.) in a differential scanning calorimetry (DSC) thermogram.

### Claim 13 (depends on 1)

The monohydrate crystalline form in claim 1, wherein the monohydrate crystalline form is MH2, having a DSC thermogram substantially in accordance with FIG. 9.

### Claim 14 (depends on 1)

The monohydrate crystalline form in claim 1, wherein the monohydrate crystalline form is MH2, exhibiting dehydration at about 25° C. to about 100° C. with a weight loss of about 4.4% in a thermogravimetric analysis (TGA).

### Claim 15 (depends on 1)

The monohydrate crystalline form in claim 1, wherein the monohydrate crystalline form is MH2, having a TGA substantially in accordance with FIG. 9.

### Claim 16 (depends on 1)

The monohydrate crystalline form in claim 1, which is at least 95, 96, 97, 98, or 99% purified.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the monohydrate crystalline form in claim 1, and a pharmaceutically acceptable excipient.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the monohydrate crystalline form is present in an amount of at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% by weight.

### Claim 19 (depends on 17)

The pharmaceutical composition of claim 17, wherein the monohydrate crystalline form is form MH1.

### Claim 20 (depends on 17)

The pharmaceutical composition of claim 17, wherein the monohydrate crystalline form is form MH2.
